NPCE
NeuroPace, Inc.
Price Chart
Latest Quote
$14.65
+0.24 (+1.67%)
Current Price
| Previous Close | $14.41 |
| Open | $14.41 |
| Day High | $14.67 |
| Day Low | $14.25 |
| Volume | 148,262 |
Stock Information
| Shares Outstanding | 34.32M |
| Total Debt | $69.93M |
| Cash Equivalents | $51.70M |
| Revenue | $106.99M |
| Net Income | $-16.17M |
| Sector | Healthcare |
| Industry | Medical Devices |
| Market Cap | $502.85M |
| EPS (TTM) | $-0.48 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $521.08M |
| Sales | $106.99M |
| Income | $-16.17M |
| Book/sh | $0.35 |
| Cash/sh | $1.51 |
| Employees | 220 |
Financial Ratios
| Quick Ratio | 3.82 |
| Current Ratio | 4.94 |
| Debt/Eq | 588.50 |
Returns & Margins
| ROA | -7.47% |
| ROE | -103.27% |
| Gross Margin | 77.38% |
| Operating Margin | -22.53% |
| Profit Margin | -17.86% |
Ownership
| Insider Ownership | 4.01% |
| Institutional Ownership | 93.89% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -65.94 |
| P/S | 4.70 |
| P/B | 42.22 |
Analyst Data
| Recommendation | none |
| Target Price | $20.22 |
Technical Indicators
| SMA20 | $14.34 |
| SMA50 | $15.22 |
| SMA200 | $15.44 |
| RSI | 47.29 |
| ATR | 0.6627 |
| Shares Float | 25.64M |
| Short Float | 2.83% |
| Short Ratio | 3.76 |
| Volatility | 1.94 |
| Rel Volume | 0.73 |
Performance History
| Week | +4.42% |
| Month | +6.55% |
| Quarter | -11.43% |
| 6 Months | +0.48% |
| YTD | -3.43% |
| Year | +64.98% |
| 3 Years | +206.49% |
| 5 Years | -24.91% |
| 10 Years | -41.31% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-08-31 | $14.65 | 148,262 |
| 2026-08-27 | $14.13 | 148,100 |
| 2026-08-26 | $14.68 | 172,800 |
| 2026-08-25 | $14.16 | 153,400 |
| 2026-08-24 | $13.99 | 117,700 |
| 2026-08-21 | $14.03 | 116,000 |
| 2026-08-20 | $14.02 | 191,800 |
| 2026-08-19 | $14.64 | 106,600 |
| 2026-08-18 | $14.47 | 140,700 |
| 2026-08-17 | $14.28 | 197,400 |
| 2026-08-14 | $14.77 | 155,000 |
| 2026-08-13 | $14.51 | 112,800 |
| 2026-08-12 | $14.56 | 186,300 |
| 2026-08-11 | $15.05 | 248,100 |
| 2026-08-10 | $14.88 | 234,500 |
| 2026-08-07 | $14.83 | 201,300 |
| 2026-08-06 | $13.90 | 286,800 |
| 2026-08-05 | $13.70 | 274,400 |
| 2026-08-04 | $14.14 | 275,100 |
| 2026-08-03 | $13.50 | 593,800 |
About NeuroPace, Inc.
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
đ° Latest News
NeuroPace Inc (NPCE) (Q2 2026) Earnings Call Highlights: Strong RNS Growth and AI Launch Offset ...
GuruFocus.com âĸ 2026-08-19T01:01:55ZNeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth
Zacks âĸ 2026-08-17T17:17:00Z
Is NeuroPace a Buy as Growth Improves but Valuation Stays Elevated?
Zacks âĸ 2026-08-17T17:06:00Z
NPCE Is Down 12.7% in 3 Months: Is the Pullback a Buying Opportunity?
Zacks âĸ 2026-08-17T16:59:00Z
NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up
Zacks âĸ 2026-08-12T15:22:00Z
NeuroPace, Inc. Q2 2026 Earnings Call Summary
Moby âĸ 2026-08-12T12:30:00Z
NeuroPace Q2 Earnings Call Highlights
MarketBeat âĸ 2026-08-12T00:04:07Z
NeuroPace, Inc. (NPCE) Reports Q2 Loss, Tops Revenue Estimates
Zacks âĸ 2026-08-11T21:25:03Z
CVRx (CVRX) Reports Q2 Loss, Beats Revenue Estimates
Zacks âĸ 2026-08-07T02:35:02Z
NeuroPace FDA Bid for Expanded Epilepsy Use Stalls as Agency Seeks More Data
MarketBeat âĸ 2026-07-28T22:04:18Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $22,766,000 | $20,821,000 | $17,299,000 | $13,027,000 |
| Cost Of Revenue | $22,766,000 | $20,821,000 | $17,299,000 | $13,027,000 |
| Total Revenue | $99,986,000 | $79,906,000 | $65,421,000 | $45,520,000 |
| Operating Revenue | $99,986,000 | $79,906,000 | $65,421,000 | $45,520,000 |
| Expenses | ||||
| Interest Expense | $7,457,000 | $8,798,000 | $8,517,000 | $7,529,000 |
| Total Expenses | $116,324,000 | $101,577,000 | $92,595,000 | $86,314,000 |
| Other Income Expense | $-486,000 | $304,000 | $-315,000 | $-337,000 |
| Other Non Operating Income Expenses | $-486,000 | $304,000 | $-315,000 | $-337,000 |
| Net Non Operating Interest Income Expense | $-4,641,000 | $-5,774,000 | $-5,467,000 | $-5,951,000 |
| Interest Expense Non Operating | $7,457,000 | $8,798,000 | $8,517,000 | $7,529,000 |
| Operating Expense | $93,558,000 | $80,756,000 | $75,296,000 | $73,287,000 |
| Selling And Marketing Expense | $46,580,000 | $39,669,000 | - | - |
| General And Administrative Expense | $19,090,000 | $17,434,000 | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-21,465,000 | $-27,141,000 | $-32,956,000 | $-47,082,000 |
| Net Interest Income | $-4,641,000 | $-5,774,000 | $-5,467,000 | $-5,951,000 |
| Interest Income | $2,816,000 | $3,024,000 | $3,050,000 | $1,578,000 |
| Normalized Income | $-21,465,000 | $-27,141,000 | $-32,956,000 | $-47,082,000 |
| Net Income From Continuing And Discontinued Operation | $-21,465,000 | $-27,141,000 | $-32,956,000 | $-47,082,000 |
| Total Operating Income As Reported | $-16,338,000 | $-21,671,000 | $-27,174,000 | $-40,794,000 |
| Net Income Common Stockholders | $-21,465,000 | $-27,141,000 | $-32,956,000 | $-47,082,000 |
| Net Income | $-21,465,000 | $-27,141,000 | $-32,956,000 | $-47,082,000 |
| Net Income Including Noncontrolling Interests | $-21,465,000 | $-27,141,000 | $-32,956,000 | $-47,082,000 |
| Net Income Continuous Operations | $-21,465,000 | $-27,141,000 | $-32,956,000 | $-47,082,000 |
| Pretax Income | $-21,465,000 | $-27,141,000 | $-32,956,000 | $-47,082,000 |
| Interest Income Non Operating | $2,816,000 | $3,024,000 | $3,050,000 | $1,578,000 |
| Operating Income | $-16,338,000 | $-21,671,000 | $-27,174,000 | $-40,794,000 |
| Gross Profit | $77,220,000 | $59,085,000 | $48,122,000 | $32,493,000 |
| Per Share | ||||
| Diluted EPS | $-0.66 | $-0.93 | $-1.27 | $-1.91 |
| Basic EPS | $-0.66 | $-0.93 | $-1.27 | $-1.91 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-12,060,000 | $-16,574,000 | $-22,834,000 | $-36,566,000 |
| Reconciled Depreciation | $1,948,000 | $1,769,000 | $1,605,000 | $2,987,000 |
| EBITDA (Bullshit earnings) | $-12,060,000 | $-16,574,000 | $-22,834,000 | $-36,566,000 |
| EBIT | $-14,008,000 | $-18,343,000 | $-24,439,000 | $-39,553,000 |
| Diluted Average Shares | $32,722,438 | $29,126,314 | $25,851,813 | $24,594,784 |
| Basic Average Shares | $32,722,438 | $29,126,314 | $25,851,813 | $24,594,784 |
| Diluted NI Availto Com Stockholders | $-21,465,000 | $-27,141,000 | $-32,956,000 | $-47,082,000 |
| Research And Development | $27,888,000 | $23,653,000 | $20,778,000 | $21,946,000 |
| Selling General And Administration | $65,670,000 | $57,103,000 | $54,518,000 | $51,341,000 |
| Other Gand A | $19,090,000 | $17,434,000 | - | - |
| Otherunder Preferred Stock Dividend | - | - | - | - |
Fetched: 2026-08-09
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $19,031,000 | $8,013,000 | $20,654,000 | $34,777,000 |
| Total Assets | $105,565,000 | $94,647,000 | $107,651,000 | $114,106,000 |
| Total Non Current Assets | $11,492,000 | $13,308,000 | $14,932,000 | $16,392,000 |
| Other Non Current Assets | $235,000 | $137,000 | $137,000 | $143,000 |
| Non Current Deferred Assets | $0 | $276,000 | $387,000 | $347,000 |
| Current Assets | $94,073,000 | $81,339,000 | $92,719,000 | $97,714,000 |
| Other Current Assets | $1,438,000 | $2,352,000 | $2,737,000 | $3,111,000 |
| Inventory | $16,896,000 | $13,381,000 | $11,214,000 | $9,712,000 |
| Receivables | $14,681,000 | $12,851,000 | $12,314,000 | $7,482,000 |
| Accounts Receivable | $14,681,000 | $12,851,000 | $12,314,000 | $7,482,000 |
| Cash Cash Equivalents And Short Term Investments | $61,058,000 | $52,755,000 | $66,454,000 | $77,409,000 |
| Cash And Cash Equivalents | $21,692,000 | $13,430,000 | $18,058,000 | $6,605,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $37,192,000 | $46,095,000 | $38,896,000 | $46,308,000 |
| Total Debt | $70,837,000 | $73,338,000 | $72,395,000 | $69,768,000 |
| Long Term Debt And Capital Lease Obligation | $68,720,000 | $71,478,000 | $70,768,000 | $68,353,000 |
| Long Term Debt | $58,884,000 | $59,525,000 | $56,954,000 | $52,913,000 |
| Current Debt And Capital Lease Obligation | $2,117,000 | $1,860,000 | $1,627,000 | $1,415,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $86,534,000 | $86,634,000 | $86,997,000 | $79,329,000 |
| Total Non Current Liabilities Net Minority Interest | $68,720,000 | $71,478,000 | $70,768,000 | $68,353,000 |
| Current Liabilities | $17,814,000 | $15,156,000 | $16,229,000 | $10,976,000 |
| Current Deferred Liabilities | $141,000 | $555,000 | $1,090,000 | $0 |
| Payables And Accrued Expenses | $15,556,000 | $12,741,000 | $13,512,000 | $9,561,000 |
| Interest Payable | $484,000 | $0 | - | - |
| Payables | $2,217,000 | $2,954,000 | $2,332,000 | $2,147,000 |
| Accounts Payable | $2,217,000 | $2,954,000 | $2,332,000 | $2,147,000 |
| Non Current Deferred Liabilities | - | - | - | $0 |
| Derivative Product Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $19,031,000 | $8,013,000 | $20,654,000 | $34,777,000 |
| Total Equity Gross Minority Interest | $19,031,000 | $8,013,000 | $20,654,000 | $34,777,000 |
| Stockholders Equity | $19,031,000 | $8,013,000 | $20,654,000 | $34,777,000 |
| Retained Earnings | $-552,415,000 | $-530,950,000 | $-503,809,000 | $-470,853,000 |
| Gains Losses Not Affecting Retained Earnings | - | - | $0 | $-1,108,000 |
| Other Equity Adjustments | - | - | - | $-1,108,000 |
| Preferred Securities Outside Stock Equity | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $33,574,759 | $30,145,039 | $27,823,465 | $25,045,751 |
| Share Issued | $33,574,759 | $30,145,039 | $27,823,465 | $25,045,751 |
| Tangible Book Value | $19,031,000 | $8,013,000 | $20,654,000 | $34,777,000 |
| Invested Capital | $77,915,000 | $67,538,000 | $77,608,000 | $87,690,000 |
| Working Capital | $76,259,000 | $66,183,000 | $76,490,000 | $86,738,000 |
| Capital Lease Obligations | $11,953,000 | $13,813,000 | $15,441,000 | $16,855,000 |
| Total Capitalization | $77,915,000 | $67,538,000 | $77,608,000 | $87,690,000 |
| Additional Paid In Capital | $571,412,000 | $538,933,000 | $524,435,000 | $506,713,000 |
| Capital Stock | $34,000 | $30,000 | $28,000 | $25,000 |
| Common Stock | $34,000 | $30,000 | $28,000 | $25,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $9,836,000 | $11,953,000 | $13,814,000 | $15,440,000 |
| Current Deferred Revenue | $141,000 | $555,000 | $1,090,000 | $0 |
| Current Capital Lease Obligation | $2,117,000 | $1,860,000 | $1,627,000 | $1,415,000 |
| Current Accrued Expenses | $13,339,000 | $9,787,000 | $11,180,000 | $7,414,000 |
| Net PPE | $11,257,000 | $12,895,000 | $14,408,000 | $15,902,000 |
| Accumulated Depreciation | $-8,206,000 | $-7,974,000 | $-7,767,000 | $-8,724,000 |
| Gross PPE | $19,463,000 | $20,869,000 | $22,175,000 | $24,626,000 |
| Leases | $2,435,000 | $2,435,000 | $2,426,000 | $2,402,000 |
| Other Properties | $10,132,000 | $11,843,000 | $13,405,000 | $14,838,000 |
| Machinery Furniture Equipment | $6,896,000 | $6,591,000 | $6,344,000 | $7,386,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $7,909,000 | $7,355,000 | $6,497,000 | $5,371,000 |
| Work In Process | $2,778,000 | $2,154,000 | $627,000 | $1,523,000 |
| Raw Materials | $6,209,000 | $3,872,000 | $4,090,000 | $2,818,000 |
| Other Short Term Investments | $39,366,000 | $39,325,000 | $48,396,000 | $70,804,000 |
| Treasury Shares Number | - | - | $0 | - |
Fetched: 2026-08-09
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-11,338,000 | $-18,255,000 | $-19,874,000 | $-37,472,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-11,006,000 | $-17,949,000 | $-19,701,000 | $-36,869,000 |
| Cash Flow From Continuing Operating Activities | $-11,006,000 | $-17,949,000 | $-19,701,000 | $-36,869,000 |
| Operating Gains Losses | $500,000 | $-229,000 | $315,000 | $356,000 |
| Investing Activities | ||||
| Capital Expenditure | $-332,000 | $-306,000 | $-173,000 | $-603,000 |
| Investing Cash Flow | $-332,000 | $8,994,000 | $23,027,000 | $23,797,000 |
| Cash Flow From Continuing Investing Activities | $-332,000 | $8,994,000 | $23,027,000 | $23,797,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-49,546,000 | $0 | - | - |
| Issuance Of Capital Stock | $69,886,000 | $3,277,000 | $7,888,000 | $0 |
| Financing Cash Flow | $19,600,000 | $4,327,000 | $8,127,000 | $490,000 |
| Cash Flow From Continuing Financing Activities | $19,600,000 | $4,327,000 | $8,127,000 | $490,000 |
| Net Other Financing Charges | $-543,000 | $-881,000 | $-564,000 | $-406,000 |
| Net Common Stock Issuance | $20,340,000 | $3,277,000 | $7,888,000 | $0 |
| Common Stock Issuance | $69,886,000 | $3,277,000 | $7,888,000 | $0 |
| Net Preferred Stock Issuance | - | - | - | - |
| Preferred Stock Issuance | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $-60,507,000 | $0 | - | $0 |
| Issuance Of Debt | $58,435,000 | $0 | - | - |
| Interest Paid Supplemental Data | $6,196,000 | $6,226,000 | $4,476,000 | $4,464,000 |
| End Cash Position | $21,814,000 | $13,552,000 | $18,180,000 | $6,727,000 |
| Beginning Cash Position | $13,552,000 | $18,180,000 | $6,727,000 | $19,309,000 |
| Changes In Cash | $8,262,000 | $-4,628,000 | $11,453,000 | $-12,582,000 |
| Proceeds From Stock Option Exercised | $1,875,000 | $1,931,000 | $803,000 | $896,000 |
| Common Stock Payments | $-49,546,000 | $0 | - | - |
| Net Issuance Payments Of Debt | $-2,072,000 | $0 | - | $0 |
| Net Long Term Debt Issuance | $-2,072,000 | $0 | - | $0 |
| Long Term Debt Payments | $-60,507,000 | $0 | - | $0 |
| Long Term Debt Issuance | $58,435,000 | $0 | - | - |
| Net Investment Purchase And Sale | $0 | $9,300,000 | $23,200,000 | $24,400,000 |
| Sale Of Investment | $0 | $9,300,000 | $23,200,000 | $24,400,000 |
| Net PPE Purchase And Sale | $-332,000 | $-306,000 | $-173,000 | $-603,000 |
| Purchase Of PPE | $-332,000 | $-306,000 | $-173,000 | $-603,000 |
| Change In Working Capital | $-4,012,000 | $-5,452,000 | $-2,484,000 | $-4,788,000 |
| Change In Other Working Capital | $-414,000 | $-534,000 | $1,090,000 | - |
| Change In Other Current Liabilities | $-1,860,000 | $-1,627,000 | $-1,415,000 | $-2,104,000 |
| Change In Payables And Accrued Expense | $2,822,000 | $-721,000 | $4,008,000 | $632,000 |
| Change In Accrued Expense | $3,552,000 | $-1,392,000 | $3,768,000 | $-15,000 |
| Change In Payable | $-730,000 | $671,000 | $240,000 | $647,000 |
| Change In Account Payable | $-730,000 | $671,000 | $240,000 | $647,000 |
| Change In Prepaid Assets | $943,000 | $384,000 | $381,000 | $-792,000 |
| Change In Inventory | $-3,673,000 | $-2,418,000 | $-1,698,000 | $-2,133,000 |
| Change In Receivables | $-1,830,000 | $-536,000 | $-4,850,000 | $-391,000 |
| Changes In Account Receivables | $-1,830,000 | $-536,000 | $-4,850,000 | $-391,000 |
| Other Non Cash Items | $775,000 | $2,571,000 | $4,065,000 | $3,066,000 |
| Stock Based Compensation | $11,089,000 | $10,282,000 | $9,558,000 | $8,349,000 |
| Asset Impairment Charge | $159,000 | $251,000 | $196,000 | $243,000 |
| Depreciation Amortization Depletion | $1,948,000 | $1,769,000 | $1,605,000 | $2,987,000 |
| Depreciation And Amortization | $1,948,000 | $1,769,000 | $1,605,000 | $2,987,000 |
| Depreciation | $1,948,000 | $1,769,000 | $1,605,000 | $2,987,000 |
| Gain Loss On Investment Securities | $-41,000 | $-229,000 | $315,000 | $356,000 |
| Gain Loss On Sale Of PPE | $14,000 | $0 | - | - |
| Net Income From Continuing Operations | $-21,465,000 | $-27,141,000 | $-32,956,000 | $-47,082,000 |
| Purchase Of Investment | - | - | - | $0 |
Fetched: 2026-08-09